Skip to content
TrialScanner

NCT03491904

To Assess the Patients' Ability to Self-Administer Fasinumab

Phase 1CompletedREGNLeadTEVACollaborator

Registry record

Lead sponsor
Regeneron Pharmaceuticals
Conditions
Osteoarthritis, Knee; Osteoarthritis, Hip
Primary completion
Jan 15, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03491904 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03491904: To Assess the Patients'... | TrialScanner